← Back to Screener
QuidelOrtho Corporation Common Stock (QDEL)
Price$14.33
Value ScoreC
Growth ScoreC
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-55.53%
Price vs S&P 500 (4W)32.69%
VGM Score43.23
Market Capitalization$977.18M
All Metrics
P/CF (Annual)9.29x
Book Value / Share (Quarterly)$27.19
P/TBV (Annual)11.89x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.80%
Cash Flow / Share (Quarterly)$-2.34
Price vs S&P 500 (YTD)-57.98%
Gross Margin (TTM)44.96%
Net Profit Margin (TTM)-45.57%
EPS (TTM)$-17.82
10-Day Avg Trading Volume1.61M
EPS Excl Extra (TTM)$-17.82
Revenue Growth (5Y)10.44%
EPS (Annual)$-16.69
ROI (Annual)-24.76%
Gross Margin (Annual)46.67%
Net Profit Margin (5Y Avg)-11.45%
Cash / Share (Quarterly)$2.06
Revenue Growth QoQ (YoY)-10.54%
ROA (Last FY)-19.62%
Revenue Growth TTM (YoY)-3.89%
EBITD / Share (TTM)$-11.78
ROE (5Y Avg)-16.05%
Operating Margin (TTM)-37.21%
Cash Flow / Share (Annual)$-1.22
P/B Ratio0.53x
P/B Ratio (Quarterly)0.56x
Net Income / Employee (Annual)$-174,100
EV / Revenue (TTM)1.33x
Net Interest Coverage (TTM)-5.28x
ROA (TTM)-20.65%
EV / EBITDA (TTM)119.08x
EPS Incl Extra (Annual)$-16.69
Current Ratio (Annual)1.50x
Quick Ratio (Quarterly)0.70x
3-Month Avg Trading Volume1.99M
52-Week Price Return-52.07%
EV / Free Cash Flow (Annual)10.05x
Revenue / Employee (TTM)$408,800
Tangible BV / Share (Quarterly)$1.95
P/S Ratio (Annual)0.36x
Asset Turnover (Annual)0.47x
52-Week High$35.58
Operating Margin (5Y Avg)-4.25%
EPS Excl Extra (Annual)$-16.69
CapEx CAGR (5Y)23.73%
Tangible BV CAGR (5Y)-9.58%
26-Week Price Return-47.61%
Quick Ratio (Annual)0.84x
13-Week Price Return-33.07%
Total Debt / Equity (Annual)1.38x
Current Ratio (Quarterly)1.43x
Enterprise Value$3.52B
Revenue / Share Growth (5Y)1.11%
Asset Turnover (TTM)0.45x
Book Value / Share Growth (5Y)-2.13%
Revenue / Employee (Annual)$420,000
Inventory Turnover (Annual)2.62x
Pretax Margin (Annual)-40.57%
Cash / Share (Annual)$2.50
3-Month Return Std Dev103.84%
Gross Margin (5Y Avg)55.37%
Net Income / Employee (TTM)$-186,300
EBITDA Interim CAGR (5Y)-42.42%
ROE (Last FY)-58.93%
Net Interest Coverage (Annual)-5.32x
EPS Basic Excl Extra (Annual)$-16.69
P/FCF (TTM)10.18x
Receivables Turnover (TTM)7.49x
EV / Free Cash Flow (TTM)27.81x
Total Debt / Equity (Quarterly)1.45x
EPS Incl Extra (TTM)$-17.82
Receivables Turnover (Annual)7.12x
ROI (TTM)-25.22%
P/S Ratio (TTM)0.37x
Pretax Margin (5Y Avg)-8.52%
Revenue / Share (Annual)$40.27
Tangible BV / Share (Annual)$3.70
Forward P/E6.19x
Price vs S&P 500 (52W)-76.44%
Year-to-Date Return-49.82%
5-Day Price Return7.99%
EPS Normalized (Annual)$-16.69
ROA (5Y Avg)-3.30%
Net Profit Margin (Annual)-41.45%
Month-to-Date Return10.06%
Cash Flow / Share (TTM)$7.04
EBITD / Share (Annual)$-10.84
Operating Margin (Annual)-33.85%
LT Debt / Equity (Annual)1.29x
P/CF (TTM)148.06x
ROI (5Y Avg)-3.74%
LT Debt / Equity (Quarterly)1.33x
EPS Basic Excl Extra (TTM)$-17.82
P/TBV (Quarterly)14.74x
P/B Ratio (Annual)1.04x
Inventory Turnover (TTM)2.49x
Pretax Margin (TTM)-44.35%
Book Value / Share (Annual)$28.28
Price vs S&P 500 (13W)-41.32%
Beta0.71x
P/FCF (Annual)13.78x
Revenue / Share (TTM)$38.96
ROE (TTM)-56.31%
52-Week Low$9.92
vGradeC
gGradeC
mGradeD
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.04est. 0.40
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.71
3.71
3.69
2.50
Industry Peers — In Vitro Diagnostics(18)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
QDELQuidelOrtho Corporation Common Stock | C | C | D | $14.33 |
| IDXXIdexx Laboratories Inc | D | B | C | $562.16 |
| LNTHLantheus Holdings, Inc | C | B | B | $100.98 |
| NNNNAnbio Biotechnology Class A Ordinary Shares | F | B | B | $22.99 |
| CLDXCelldex Therapeutics, Inc | F | F | C | $28.62 |
| NEOGNeogen Corp | C | C | B | $8.90 |
| NTLAIntellia Therapeutics, Inc | D | C | B | $13.54 |
| ACHVAchieve Life Sciences, Inc. | F | F | B | $5.13 |
| MYGNMyriad Genetics Inc | C | C | C | $4.57 |
| TKNOAlpha Teknova, Inc. Common Stock | C | C | B | $4.56 |
| IMDXInsight Molecular Diagnostics Inc. Common Stock | F | D | C | $5.24 |
About
QuidelOrtho Corp develops and manufactures rapid diagnostic testing solutions, including immunoassay, molecular testing, clinical chemistry, and transfusion medicine products. The company operates globally across North America, Europe, the Middle East and Africa, China, and other markets, with North America generating the majority of its revenue.